Skip to Content

Arch Biopartners Inc ACHFF

Morningstar Rating
$1.11 +0.05 (4.25%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

ACHFF is trading at a 35% discount.
Price
$1.06
Fair Value
$5.55
Uncertainty
Extreme
1-Star Price
$92.38
5-Star Price
$4.86
Economic Moat
Hwqb
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ACHFF is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$1.06
Day Range
$1.051.11
52-Week Range
$0.721.90
Bid/Ask
$1.06 / $1.11
Market Cap
$69.34 Mil
Volume/Avg
24,800 / 14,177

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Arch Biopartners Inc is a clinical stage company developing technologies with the potential to make medical or commercial impacts. The company is developing a drug platform Metablok to produce drug candidates to inhibit organ inflammation caused via the DPEP-1 pathway. It's under development portfolio is AB569, a potential new treatment for antibiotic resistant bacterial infections in the lungs or wounds; and, Borg peptide coatings that increase corrosion resistance and decrease bacterial biofilm on various medical grade metals and plastics.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees

Comparables

Valuation

Metric
ACHFF
NYKD
HLVX
Price/Earnings (Normalized)
Price/Book Value
3.832.38
Price/Sales
40.74
Price/Cash Flow
Price/Earnings
ACHFF
NYKD
HLVX

Financial Strength

Metric
ACHFF
NYKD
HLVX
Quick Ratio
0.196.9517.12
Current Ratio
0.206.9517.58
Interest Coverage
−8.31−59.70
Quick Ratio
ACHFF
NYKD
HLVX

Profitability

Metric
ACHFF
NYKD
HLVX
Return on Assets (Normalized)
−89.80%−19.18%−30.32%
Return on Equity (Normalized)
−26.31%−36.74%
Return on Invested Capital (Normalized)
−30.96%−34.21%
Return on Assets
ACHFF
NYKD
HLVX
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRZfpd$537.7 Bil
VRTX
Vertex Pharmaceuticals IncQybbdht$108.4 Bil
REGN
Regeneron Pharmaceuticals IncVxptdf$104.6 Bil
MRNA
Moderna IncBjry$33.4 Bil
ARGX
argenx SE ADRLfmj$23.7 Bil
BNTX
BioNTech SE ADRGysv$22.0 Bil
ALNY
Alnylam Pharmaceuticals IncBfgpq$19.5 Bil
BMRN
Biomarin Pharmaceutical IncMyytgzs$16.7 Bil
RPRX
Royalty Pharma PLC Class ALrfmpjt$14.0 Bil
INCY
Incyte CorpVgpbpn$13.5 Bil

Sponsor Center